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Abstract. Mass drug administration (MDA) with azithromycin may reduce under-5 child mortality (U5M) in sub-
Saharan Africa. Here, we conducted a pooled analysis of all published cluster-randomized trials evaluating the effect of
azithromycin MDA on child mortality. We pooled data from cluster-randomized trials randomizing communities to azi-
thromycin MDA versus control. We calculated mortality rates in the azithromycin and control arms in each study, and by
country for multisite studies including multiple countries. We conducted a two-stage individual community data meta-
analysis to estimate the effect of azithromycin for prevention of child mortality. Three randomized controlled trials in four
countries (Ethiopia, Malawi, Niger, and Tanzania) were identiﬁed. The overall pooled mortality rate was 15.9 per 1,000
person-years (95% conﬁdence interval [CI]: 15.5–16.3). The pooled mortality rate was lower in azithromycin-treated
communities than in placebo-treated communities (14.7 deaths per 1,000 person-years, 95% CI: 14.2–15.3 versus 17.2
deaths per 1,000 person-years, 95% CI: 16.5–17.8). There was a 14.4% reduction in all-cause child mortality in com-
munities receiving azithromycin MDA (95% CI: 6.3–21.7% reduction, P = 0.0007). All-cause U5M was lower in com-
munities receiving azithromycinMDA than in control communities, suggesting that azithromycinMDAcould be a new tool
to reduce child mortality in sub-Saharan Africa. However, heterogeneity in effect estimates suggests that the magnitude
of the effect may vary in time and space and is currently not predictable.
INTRODUCTION
More than 700 million doses of azithromycin have been
distributed to trachoma-endemic districts as part of trachoma
control.1 Annual mass drug administration (MDA) with azi-
thromycin dramatically reduces the prevalence of Chlamydia
trachomatis, the causative organism of trachoma.2,3 Collateral
effectsofazithromycinMDAmay include reduction in infectious
burden, including malaria parasitemia,4,5 upper respiratory in-
fection,6 and diarrhea,7 and improving nutritional status.8–10
Unintended but beneﬁcial effects of mass azithromycin distri-
bution may lead to improvements in child health at the pop-
ulation level that extend beyond those for trachoma control.
In a cluster-randomized trial of azithromycin MDA for tra-
choma control, communities receiving azithromycin had sig-
niﬁcantly decreased all-cause child mortality compared with
communities receiving no treatment.11 In a subsequent three-
country study designed speciﬁcally to assess the efﬁcacy of
azithromycin MDA for reduction in child mortality, biannual
azithromycin MDA to preschool children decreased all-cause
child mortality by 13.5% compared with communities receiv-
ing placebo.12 However, the efﬁcacy of mass azithromycin for
the reduction in mortality differed substantially across the sites
included in the trial, although there was no statistically signiﬁ-
cant difference between the countries. The strongest effect
by far was seen in the Niger site, which had the highest base-
line child mortality rate, the greatest number of child-years of
observations, the lowest loss to follow-up, and the highest
coverage with MDA. As such, the greatest number of events to
report on arose from Niger.
Here, we assess the sum of the evidence of the effect of
azithromycin MDA on child mortality in a pooled analysis
of cluster-randomized trials. We further sought to address
sourcesof heterogeneity of effects of the relationshipbetween
azithromycin MDA and child mortality.
METHODS
To identify trials, we searched Medline using the key words
“mortality” and “azithromycin or zithromax” from inception
through November 22, 2018. Titles and abstracts were reviewed
by the C. E. O., and studies that met the inclusion criteria were
included in the pooled analysis. Trials were eligible for inclusion in
the pooled analysis if they randomized communities to azi-
thromycinMDAstrategiesandreportedall-causechildmortalityas
a prespeciﬁed outcome. Individually randomized studies were
excluded as the research question was focused on community-
level mass azithromycin distribution for prevention of child mor-
tality. Studies reporting any azithromycin indication (e.g., for
trachoma control or not) were eligible for inclusion. Studies were
eligible for inclusion if they prespeciﬁed themortality outcome and
thestatistical analysisplanapriori. Theoutcomeof interestwasall-
cause mortality in children aged less than 5 years. We used indi-
vidual data fromeach trial to estimate the effect of azithromycinon
all-cause mortality in children up to 59 months of age, even if the
original study reported a wider age range. Only children in an age
range that was eligible for treatment were included in the analysis.
Characteristics of included studies. Characteristics of
studies included in the pooled analysis are summarized in
Table 1.
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The Trachoma Amelioration in Northern Amhara (TANA)
study was a four-arm community-randomized trial of azi-
thromycin MDA strategies for trachoma control, including an-
nual (ages³ 1year), biannual (ages³ 1year), quarterly (ages1–9
years), and delayed treatment.11,13 Trachoma Amelioration in
Northern Amhara took place in Amhara, Ethiopia, andmortality
resultswere reported for theperiod from2006 to2007.Mortality
was measured via a door-to-door census annually before the
annual treatment phase. Communities were followed for
12 months, and all-cause child mortality was a prespeciﬁed
secondary outcome. In this analysis, we restricted mortality
data only to children aged 12–59 months for consistency with
other studies. Children less than 12 months of age were not
treated in TANA and, thus, were not included in this analysis.
The Partnership for the Rapid Elimination of Trachoma
(PRET) study was a three-country study of annual azi-
thromycin MDA (ages ³ 6 months) compared with only bi-
annual treatment of children (ages 6 months–12 years).
Mortality data were available and prespeciﬁed as a secondary
outcome for the Niger study.14,15 In Niger, communities were
randomized in a 1:1:1:1 ratio to annual azithromycinMDAwith
an 80% coverage target, annual azithromycin MDA with a
90% coverage target, biannual azithromycin MDA with 80%
coverage, or biannual azithromycin MDA with 90% coverage.
Mortality was determined by a door-to-door census con-
ductedbefore eachannual treatment phase. Thecommunities
were followed for 36months.Children aged6–59monthswere
included in the mortality analysis.
The Macrolide Oraux pour Re´duire les De´ce`s avec un Oeil
sur la Re´sistance (MORDOR) study was a placebo-controlled
community-randomized trial conducted in Malawi, Niger, and
Tanzania.12 Thecommunitieswere randomized in a1:1 ratio to
biannual azithromycinMDAorbiannual placebodistribution to
preschool children (ages 1–59 months). Mortality was mea-
sured via a door-to-door census conducted before each
treatment phase. Communities were followed for a 24-month
period, and the primary prespeciﬁed outcome was all-cause
mortality as determined by the census. Children aged 1–59
months were included in the mortality analysis.
Each included study was reviewed and approved by the
appropriate ethical committee, including the Committee on
HumanResearch at theUniversity of California, SanFrancisco
(TANA, PRET, MORDOR); the Ethiopian Science and Tech-
nology Commission (TANA); and the Institutional Review
Boards at Emory University (TANA, MORDOR), the College
of Medicine, University of Malawi, Blantyre (MORDOR), the
Niger Ministry of Health (PRET, MORDOR), the Tanzanian
National Institute for Medical Research (MORDOR), the Lon-
don School of Hygiene and Tropical Medicine (MORDOR),
and JohnsHopkinsUniversity School ofMedicine (MORDOR).
The pooled analysis used de-identiﬁed community-level ag-
gregate data and did not require additional ethical review.
Statistical methods.We conducted a two-stage individual
community data meta-analysis using community-level data
from each study. All analyses were conducted at the com-
munity level (the level of randomization) to account for the
cluster-randomized nature of the studies and were intention-
to-treat. For the ﬁrst stage, we calculated incidence rate ratios
(IRRs) for each country from each study separately using a
negative binomial model. We then used the individual study
IRRsand their variances andpooled the estimates into a single
summary measure using a random effects model, with a
separate random effect for each country from each study (ﬁve
random effects total) using the metafor package in R (The R
Foundation for Statistical Computing, Vienna, Austria). A re-
stricted maximum likelihood (REML) estimator was used to
estimate τ2.We estimated heterogeneity across trials with the
I2 statistic. The primary analysis considered each country and
each trial separately to assess heterogeneity by country (e.g.,
including both geography and background mortality rates at
the time the studywasconducted). Toestimate thepooled risk
difference, we calculated study-speciﬁc incidence rates in the
azithromycin andcontrol armsandused randomeffectsmeta-
analysis with an REML estimator to calculate the pooled es-
timate. We assessed heterogeneity of effect estimates by
country of origin and the background under-5 child mortality
rate (U5MR) as determined by the mortality rate in the control
arm of the study. We built separate random effects models for
each moderator of interest using the metafor command in R.
As a sensitivity analysis, we repeated the primary analysis
excluding one study inwhich all communities received at least
annual azithromycin MDA (e.g., excluding the PRET-Niger
study).16 All analyses were conducted in R.
RESULTS
A total of 449 unique titles and abstracts were identiﬁed and
reviewed. Reasons for exclusion included that the study did
TABLE 1
Studies included in the pooled analysis
Country Study Years of study
Country child
mortality rate,* per
1,000 live births
Child mortality rate* in
control arm per 1,000
person-years
Number of
communities Azithromycin intervention Control intervention
Ethiopia TANA 2006–2007 103.5 8.3 48 Annual, biannual or quarterly
mass azithromycin
Delayed mass azithromycin
distribution
Niger PRET 2010–2013 116.1 35.3 48 Biannual mass azithromycin
to children < 12 years
Annual mass azithromycin to
the entire community
Niger MORDOR 2015–2017 93.2 27.5 594 Biannual mass azithromycin
to children aged 1–59 months
Biannual placebo to children
aged 1–59 months
Malawi MORDOR 2015–2017 57.1 9.6 304 Biannual mass azithromycin
to children aged 1–59 months
Biannual placebo to children
aged 1–59 months
Tanzania MORDOR 2015–2017 57.8 5.5 614 Biannual mass azithromycin
to children aged 1–59 months
Biannual placebo to children
aged 1–59 months
MORDOR = Macrolide Oraux pour Re´duire les De´ce`s avec un Oeil sur la Re´sistance; PRET = Partnership for the Rapid Elimination of Trachoma; TANA = Trachoma Amelioration in Northern
Amhara.
* Child mortality rates as estimated by United Nations International Children’s Emergency Fund (UNICEF) are expressed in number of deaths per 1,000 live births; mortality rates as estimated by
the control arm in each trial aremortality rates per 1,000 person-years.Mortality rates per 1,000 person-years estimate the number of deaths per 1,000 persons per year, whereasmortality rates per
1,000 live births are the probability (per 1,000 live births) of a child dying before his or her ﬁfth birthday (e.g., over a 5-year period).
692 OLDENBURG AND OTHERS
not meet the inclusion criteria (e.g., was nonrandomized or
individuals randomized, in adults; did not evaluate azi-
thromycin; or did not report mortality, N = 194); was an
editorial, review, case report, or other non-empirical report
(N = 190); or was a nonhuman study (N = 62). We identiﬁed
three cluster-randomized trials undertaken in 1,608 commu-
nities from four countries (e.g., Ethiopia, Malawi, Niger, and
Tanzania) that met the inclusion criteria.11,12,16 Azithromycin
interventions included annual, biannual, and quarterly MDA to
the whole community or to children only (Table 1). Control
communities included distribution of matching placebo
(MORDOR), delayed azithromycin MDA (TANA), and annual
azithromycin MDA (standard of care for trachoma-endemic
communities, PRET). Across all studies and all sites, a total of
5,486 deaths were observed over 344,905 person-years
(mortality rate 15.9 per 1,000 person-years, 95% CI: 15.3–16.1).
In azithromycin-treated communities, the mortality rate was 14.4
per 1,000 person-years (95%CI: 13.9–15.0), comparedwith 17.0
per 1,000 person-years (95% CI: 16.4–17.6) in untreated
communities.
Across all studies and countries, in a random effects model
taking into account between-study heterogeneity, therewas a
14.4% reduction in mortality in communities that received
azithromycin MDA versus control communities (pooled IRR:
0.856, 95%CI: 0.783–0.937, P = 0.0007; Figure 1). There was
moderate heterogeneity across studies (I2 = 22.6%, P = 0.11).
The pooled incidence rate differencewas 2.9 fewer deaths per
1,000person-years in azithromycin-treated communities than
in placebo communities (95% CI: −5.6 to −0.3 deaths per
1,000 person-years, P = 0.03). The results were robust to ex-
clusion of the PRET-Niger study, in which the control arm
included annual mass azithromycin distribution (pooled IRR:
0.865, 95% CI: 0.770–0.972, P = 0.02).
We explored several sources of heterogeneity, including
country andbackgroundchildmortality rate. Study siteswith a
highermortality rate in the placebo arm tended to have greater
absolute differences in the rate of child mortality between the
azithromycin and the placebo arm (Figure 2). However, in a
meta-regression model, there was no signiﬁcant effect mod-
iﬁcation by mortality rate in the placebo arm (P = 0.12), al-
though in general the effect sizes increased with increasing
baselinemortality rate. Effectmodiﬁcation by country of origin
was not statistically signiﬁcant (P = 0.06).
DISCUSSION
Across three studies in four countries that met our inclusion
criteria, under-5 child mortality (U5M) was 14% lower in
communities receiving azithromycin MDA than in control
communities, although effect estimates between studies
showed some degree of heterogeneity. It is tempting to hy-
pothesize that heterogeneity was driven primarily by the
background mortality rate, but there was no signiﬁcant dif-
ference by child mortality rate or country of the study site.
However, detection of effect modiﬁcation is difﬁcult in studies
of rare outcomes such as child mortality.17 Even in this large
pooled analysis, detection of statistically signiﬁcant effect
modiﬁcation may not be possible. The potential absolute
number of lives savedwith azithromycinMDAwill be greater in
scenarios with more child mortality events (higher baseline
U5MR, or areas with an outbreak or epidemic of disease
amenable to treatment with azithromycin), even if the pro-
portion is similar between settings overall. In general, studies
conducted in communities with higher baseline mortality had
larger effect sizes, indicating that azithromycin MDA may be
the most efﬁcacious in high child mortality burden settings.
Child mortality continues to decline over time in many regions
of sub-Saharan Africa.18 It is possible that geographic in-
dication of azithromycin for child mortality reduction could
differ across space and time.
Although the reason for the differences in efﬁcacy of azi-
thromycin MDA in each study setting is unclear, there are
several potential reasons why efﬁcacy may differ. Under-5
child mortality is not normally distributed and the underlying
causality may vary greatly in time and space. If the underlying
mortality driver is periodic outbreaks or epidemics of viral
meningitis or rotavirus, for example, the effect of azithromycin
MDA is likely to be far less than in a setting in which bacterial
respiratory tract infection, bacterial diarrhea, and/or malaria is
the driver of high mortality. In general, the largest effect sizes
were seen in countries with larger mortality rates in the pla-
cebo arm and higher country-level mortality rates, larger
samples, and higher coverage with azithromycin MDA. Child
mortality is a rare event even in high-burden settings. In low-
and medium-burden settings where child mortality is a very
rare event, absolute effect sizes will necessarily be small, and
there will be limited power to detect relative differences. Dif-
ferences in causes of death by study site or time point may
affect the efﬁcacy of azithromycin, for example, if causes of
death in one location aremore often an infectious agent that is
susceptible to azithromycin than others. Differences in back-
ground antibiotic use and susceptibility to macrolides of
bacterial pathogens may also contribute to heterogeneity.
Azithromycin distribution may have reduced efﬁcacy for pre-
vention of mortality in areas that have increased macrolide
resistance. It is possible that underlying pathogens that con-
tributed to mortality and morbidity or their antibiotic suscep-
tibilities differed across geography and time in the included
studies.
FIGURE 1. Forest plot of incidence rate ratios for studies included in
the pooled analysis. Studies evaluated child mortality rates in com-
munities receiving mass drug administration with azithromycin com-
pared with control (placebo distribution in Macrolide Oraux pour
Re´duire les De´ce`s avec un Oeil sur la Re´sistance [MORDOR], annual
azithromycin in Partnership for the Rapid Elimination of Trachoma
[PRET], and delayed treatment in Trachoma Amelioration in Northern
Amhara [TANA]). Data were included for children aged 1–59months in
MORDOR, 6–59 months in PRET, and 12–59 months in TANA.
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Some heterogeneity in study-speciﬁc effects is likely be-
cause of the design of individual studies included in this
analysis. The cluster-randomized trials that were designed for
trachoma endpoints included in this analysis did not include a
placebo control group.11,16 This could cause bias in outcome
assessment, given that census activities were tied to treat-
ment activities. The biggest anticipated threat would be that
fewer deaths would be discovered in untreated communities
because census/treatment teams would not have contact
with these communities during the study. Such bias does not
seem to have been present, however, because a protective
effect of azithromycin MDA on mortality was observed even
in studies with an untreated control group. However, if deaths
were missed in the untreated arm of these studies, these
results could be an underestimate of the true effect of azi-
thromycin MDA.
Trachoma studies have demonstrated that azithromycin
MDA leads to selection for macrolide resistance in some
organisms, including Streptococcus pneumoniae19–22 and
Escherichia coli.23–25 However, resistance selection in the
most commonly used therapeutic antibiotic classes for
childhood infection in sub-Saharan Africa (penicillins and
sulfamethoxazole) has generally not been found.6,19,21 Tra-
choma programs distribute millions of doses of azithromycin
annually,26 of which approximately 15% are administered
to children of ages 6 months to 5 years. Health districts are
targeted for a predetermined number of years (1, 3, or 5) de-
termined by the baseline prevalence of clinical signs of tra-
choma children.
Programmatic use of azithromycin MDA for the prevention
of child mortality could introduce additional macrolide selec-
tion pressure if it were not similarly time limited. Therefore,
understanding the drivers of heterogeneity in treatment ef-
fects in time and space is essential for targeting azithromycin
interventions to regions that would beneﬁt the most to mini-
mize resistance. The results of the present analysis suggest
that considerationof baselinechildmortality rates (whichdiffer
over time and with geography), the size of the population
targeted, and the anticipated coverage rate may be important
when deciding where to implement azithromycin MDA to re-
duce U5M.
The results of this studymust be interpreted in thecontext of
several limitations. As previously described, not all studies
included a placebo arm. Treatment and control strategies
differed across studies, which likely introduced additional
heterogeneity. Detection of heterogeneity in treatment effects
(effect modiﬁcation) with rare outcomes is difﬁcult even in
large trials.17 Although individual study results differed quali-
tatively across space and time, there were no statistically
signiﬁcant effect modiﬁers. To date, only a limited number of
studies have evaluated the efﬁcacy of azithromycin for child
mortality. All studies included in this pooled analysis were
conducted by the same group of investigators. If azithromycin
MDA is scaled up in the context of child mortality reduction
programs, continual evaluation of the effectiveness of the in-
tervention will be essential to determine when to stop.
The results of this analysis demonstrate a signiﬁcant pro-
tective effect of azithromycin MDA to preschool children on
FIGURE 2. Risk differences and 95% conﬁdence intervals for rate of mortality in azithromycin-treated communities compared with placebo-
treated communities. The red dotted line with short dashes indicates 0 deaths averted per 1,000 person-years (no effect). The gray dotted line with
longdashes indicates thepooledeffect estimate (−2.9deathsavertedper 1,000person-years).MORDOR=MacrolideOrauxpourRe´duire lesDe´ce`s
avec unOeil sur la Re´sistance; PRET =Partnership for the Rapid Elimination of Trachoma; TANA= TrachomaAmelioration in Northern Amhara. This
ﬁgure appears in color at www.ajtmh.org.
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all-cause mortality in studies reported over a nearly 10-year
period. There was some heterogeneity in effect estimates,
likely reﬂecting both changes over time and space, and dif-
ferences in study design. Although the precise mechanism
of action of azithromycin for prevention of child mortality re-
mains unknown, these results indicate a potentially important
role of azithromycin MDA for mortality reduction in sub-
Saharan Africa.
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